Pacira BioSciences Announces Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference
06 9월 2023 - 9:00PM
Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced its
participation in an analyst-led fireside chat at the H.C.
Wainwright 25th Annual Global Investment Conference. The
pre-recorded audio of the virtual event can be accessed beginning
Monday, September 11th at 7:00AM ET by visiting the “Events” page
of the company’s website at investor.pacira.com. A replay of the
webcast will also be available for two weeks.
About Pacira
Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to
providing a non-opioid option to as many patients as possible to
redefine the role of opioids as rescue therapy only. The company is
also developing innovative interventions to address debilitating
conditions involving the sympathetic nervous system, such as
cardiac electrical storm, chronic pain, and spasticity. Pacira has
three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine
liposome injectable suspension), a long-acting, local analgesia
currently approved for postsurgical pain management; ZILRETTA®
(triamcinolone acetonide extended-release injectable suspension),
an extended-release, intra-articular, injection indicated for the
management of osteoarthritis knee pain; and ioveraº®, a novel,
handheld device for delivering immediate, long-acting, drug-free
pain control using precise, controlled doses of cold temperature to
a targeted nerve. To learn more about Pacira, including the
corporate mission to reduce overreliance on opioids, visit
www.pacira.com.
Company Contact:
Pacira BioSciences, Inc.
Christian Pedetti
(973) 254-4387
Christian.pedetti@pacira.com
Pacira BioSciences (NASDAQ:PCRX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Pacira BioSciences (NASDAQ:PCRX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024